3 research outputs found
ΠΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½Π°Ρ ΡΠ°ΡΠΊΠΎΠΈΠ΄ΠΎΠ·ΠΎ-ΠΏΠΎΠ΄ΠΎΠ±Π½Π°Ρ ΡΠ΅Π°ΠΊΡΠΈΡ Π½Π° ΡΠΎΠ½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ ΡΠΎΡΠ΅ΠΊ
Immune checkpoint inhibitors are associated with a wide spectrum of immune-related adverse events (AE) of different severity. Immune-related sarcoidosis-like reactions are relatively rare but clinically important AEs. These abnormalities, due to the appearance of active pathological lymph nodes or nodules in other organs on radiographs, can be falsely interpreted as tumor progression or stabilization and thus affect treatment strategy, leading to unreasonably early therapy discontinuation or its unnecessary continuation. So far there were no convincing criteria for differentiation between sarcoidosis-like reaction and sarcoidosis, oncologist should be aware of this reaction and include it in the differential diagnosis in patient with suspected disease progression who are treated with immune checkpoint inhibitors.ΠΡΠΈΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ ΠΌΠΎΠΆΠ΅Ρ ΡΠΎΠΏΡΠΎΠ²ΠΎΠΆΠ΄Π°ΡΡΡΡ ΡΠ°Π·Π²ΠΈΡΠΈΠ΅ΠΌ ΠΈΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
ΠΎΡΠ»ΠΎΠΆΠ½Π΅Π½ΠΈΠΉ ΡΠ°ΠΌΠΎΠ³ΠΎ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ ΡΠΏΠ΅ΠΊΡΡΠ° ΠΈ ΡΡΠ΅ΠΏΠ΅Π½ΠΈ ΡΡΠΆΠ΅ΡΡΠΈ. ΠΠ΄Π½ΠΈΠΌ ΠΈΠ· Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ ΡΠ΅Π΄ΠΊΠΈΡ
, Π½ΠΎ Π²Π°ΠΆΠ½ΡΡ
ΠΏΠΎ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠΈ, ΡΠ²Π»ΡΡΡΡΡ ΠΈΠΌΠΌΡΠ½ΠΎΠΎΠΏΠΎΡΡΠ΅Π΄ΠΎΠ²Π°Π½Π½ΡΠ΅ ΡΠ°ΡΠΊΠΎΠΈΠ΄ΠΎΠ·ΠΎ-ΠΏΠΎΠ΄ΠΎΠ±Π½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ. ΠΠ°Π½Π½ΡΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ, Π·Π° ΡΡΠ΅Ρ ΡΠ΅Π½ΡΠ³Π΅Π½ΠΎΠ³ΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ Π°ΠΊΡΠΈΠ²Π½ΡΡ
ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΡ
Π»ΠΈΠΌΡΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΡΠ·Π»ΠΎΠ² ΠΈΠ»ΠΈ ΡΠ·Π΅Π»ΠΊΠΎΠ² Π² ΠΈΠ½ΡΡ
ΠΎΡΠ³Π°Π½Π°Ρ
, ΠΌΠΎΠ³ΡΡ Π±ΡΡΡ Π»ΠΎΠΆΠ½ΠΎ ΡΡΠ°ΠΊΡΠΎΠ²Π°Π½Ρ ΠΊΠ°ΠΊ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈΠ»ΠΈ ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΡ ΠΎΡΠ½ΠΎΠ²Π½ΠΎΠ³ΠΎ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡ ΠΈ, ΡΠ°ΠΊΠΈΠΌ ΠΎΠ±ΡΠ°Π·ΠΎΠΌ, ΠΏΠΎΠ²Π»ΠΈΡΡΡ Π½Π° ΡΠ°ΠΊΡΠΈΠΊΡ Π»Π΅ΡΠ΅Π½ΠΈΡ, ΠΏΡΠΈΠ²ΠΎΠ΄Ρ ΠΊ Π½Π΅ΠΎΠ±ΠΎΡΠ½ΠΎΠ²Π°Π½Π½ΠΎ ΡΠ°Π½Π½Π΅ΠΉ ΠΎΡΠΌΠ΅Π½Π΅ ΡΠ΅ΡΠ°ΠΏΠΈΠΈ ΠΈΠ»ΠΈ Π΅Ρ Π½Π΅Π½ΡΠΆΠ½ΠΎΠΌΡ ΠΏΡΠΎΠ΄ΠΎΠ»ΠΆΠ΅Π½ΠΈΡ. ΠΠ²ΠΈΠ΄Ρ ΠΎΡΡΡΡΡΡΠ²ΠΈΡ Π½Π° Π½Π°ΡΡΠΎΡΡΠΈΠΉ ΠΌΠΎΠΌΠ΅Π½Ρ ΡΠ±Π΅Π΄ΠΈΡΠ΅Π»ΡΠ½ΡΡ
ΠΊΡΠΈΡΠ΅ΡΠΈΠ΅Π² ΠΎΡΠ»ΠΈΡΠΈΡ ΡΠ°ΡΠΊΠΎΠΈΠ΄ΠΎΠ·ΠΎ-ΠΏΠΎΠ΄ΠΎΠ±Π½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ ΠΈ ΡΠ°ΡΠΊΠΎΠΈΠ΄ΠΎΠ·Π°, Π½Π΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΠ° ΠΎΡΠ²Π΅Π΄ΠΎΠΌΠ»Π΅Π½Π½ΠΎΡΡΡ ΠΎΠ½ΠΊΠΎΠ»ΠΎΠ³ΠΎΠ² ΠΎ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ ΠΏΠΎΠ΄ΠΎΠ±Π½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π΄Π»Ρ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΈΡ Π΅Π΅ Π² Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΡΠΉ Π΄ΠΈΠ°Π³Π½ΠΎΠ· ΠΏΡΠΈ ΠΏΠΎΠ΄ΠΎΠ·ΡΠ΅Π½ΠΈΡΡ
Π½Π° ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Ρ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ², ΠΏΠΎΠ»ΡΡΠ°ΡΡΠΈΡ
ΠΈΠΌΠΌΡΠ½ΠΎΡΠ΅ΡΠ°ΠΏΠΈΡ ΠΈΠ½Π³ΠΈΠ±ΠΈΡΠΎΡΠ°ΠΌΠΈ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ
ΡΠΎΡΠ΅ΠΊ
ΠΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ²-ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π² ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠ΅ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ ΠΏΡΠΈ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠΉ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ
Background. The search for molecular markers of colon diseases allowing highly specific and sensitive identification and differentiation of pathological processes is a clinically important problem. Expression levels of genes responsible for proliferation can reflect the changes in the affected tissues. The study objective is to perform comparative analysis of molecular and genetic markers of proliferative activity in benign and malignant neoplasms of the colon. Materials and methods. Analysis of the changes in proliferation markers (CCND1, Ρ-MYC, Ki-67, HER2neu, TERT) in adenocarcinoma of the colon (n = 259), resection margin (about 15β20 cm from the tumor lesion) (n = 251), unchanged colon mucosa from healthy donors (n = 247), polyps (n = 28), unchanged colon mucosa intestinal polyposis (10β15 cm from the polyp) (n = 75) was performed using RT-PCR. Results and conclusion. It was shown that morphologically unchanged tissue of intestinal mucosa in malignant tumors has significant differences from normal tissue of healthy donors. Significant differences in the level of expression of genes responsible for the processes of proliferation, Ρ-MYC, CCND1, TERT were found in benign hyperproliferative diseases (polyps). Moreover, these changes were specific to the type of pathological process, which allows us to consider these genes as the most promising candidates in the development of a differential method for diagnosing colon diseases.ΠΠ²Π΅Π΄Π΅Π½ΠΈΠ΅. ΠΠΎΠΈΡΠΊ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ, ΡΠΏΠΎΡΠΎΠ±Π½ΡΡ
Ρ Π²ΡΡΠΎΠΊΠΎΠΉ ΡΡΠ²ΡΡΠ²ΠΈΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΠΈ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡΡ Π²ΡΡΠ²Π»ΡΡΡ ΠΈ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΡΠΎΠ²Π°ΡΡ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΉ ΠΏΡΠΎΡΠ΅ΡΡ, ΡΠ²Π»ΡΠ΅ΡΡΡ Π°ΠΊΡΡΠ°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΈ Π²Π°ΠΆΠ½ΠΎΠΉ Π·Π°Π΄Π°ΡΠ΅ΠΉ. Π£ΡΠΎΠ²Π΅Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ², ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π° ΠΏΡΠΎΡΠ΅ΡΡΡ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ, ΠΌΠΎΠΆΠ΅Ρ ΠΎΡΡΠ°ΠΆΠ°ΡΡ ΠΊΠ°ΡΡΠΈΠ½Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ Π² ΡΠΊΠ°Π½ΡΡ
ΠΏΠΎΡΠ°ΠΆΠ΅Π½Π½ΠΎΠ³ΠΎ ΠΎΡΠ³Π°Π½Π°. Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΡΡΠ°Π²Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ Π°Π½Π°Π»ΠΈΠ· ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎ-Π³Π΅Π½Π΅ΡΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΏΡΠΈ Π΄ΠΎΠ±ΡΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ
Π½ΠΎΠ²ΠΎΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡΡ
ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ. ΠΠ°ΡΠ΅ΡΠΈΠ°Π»Ρ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΠ΅ΡΠΎΠ΄ΠΎΠΌ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠ°Π·Π½ΠΎΠΉ ΡΠ΅ΠΏΠ½ΠΎΠΉ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΌ Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ Π°Π½Π°Π»ΠΈΠ· ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ°ΡΠΊΠ΅ΡΠΎΠ² ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ (CCND1, Ρ-MYC, Ki-67, HER2neu, TERT) Π² ΡΠ»Π΅Π΄ΡΡΡΠΈΡ
ΡΠΊΠ°Π½ΡΡ
: Π°Π΄Π΅Π½ΠΎΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌΡ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ (n = 259), ΠΊΡΠ°Ρ ΡΠ΅Π·Π΅ΠΊΡΠΈΠΈ (ΠΎΠΊΠΎΠ»ΠΎ 15β20 ΡΠΌ ΠΎΡ ΠΎΠΏΡΡ
ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠ·Π»Π°) (n = 251), Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΠΎΠΉ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ Π·Π΄ΠΎΡΠΎΠ²ΡΡ
Π΄ΠΎΠ½ΠΎΡΠΎΠ² (n = 247), ΠΏΠΎΠ»ΠΈΠΏΠΎΠ² (n = 28), Π½Π΅ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΠΎΠΉ ΡΠ»ΠΈΠ·ΠΈΡΡΠΎΠΉ ΠΎΠ±ΠΎΠ»ΠΎΡΠΊΠΈ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ ΠΏΡΠΈ ΠΏΠΎΠ»ΠΈΠΏΠ°Ρ
(10β15 ΡΠΌ ΠΎΡ ΠΏΠΎΠ»ΠΈΠΏΠ°) (n = 75). Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ Π·Π°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π£ΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π² ΡΠΊΠ°Π½ΡΡ
ΠΏΠΎΠ»ΠΈΠΏΠΎΠ² ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ Π½Π°Π±Π»ΡΠ΄Π°ΡΡΡΡ Π΄ΠΎΡΡΠΎΠ²Π΅ΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ Π² ΡΡΠΎΠ²Π½Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ², ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΡΡ
Π·Π° ΠΏΡΠΎΡΠ΅ΡΡΡ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ (Ρ-MYC, CCND1, TERT). ΠΡΡΠ²Π»Π΅Π½Π½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½Ρ Π΄Π»Ρ ΡΠΈΠΏΠ° ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠΎΡΠ΅ΡΡΠ°, ΡΡΠΎ ΠΏΠΎΠ·Π²ΠΎΠ»ΡΠ΅Ρ ΡΠ°ΡΡΠΌΠ°ΡΡΠΈΠ²Π°ΡΡ Π΄Π°Π½Π½ΡΠ΅ Π³Π΅Π½Ρ Π² ΠΊΠ°ΡΠ΅ΡΡΠ²Π΅ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Π½ΡΡ
ΠΊΠ°Π½Π΄ΠΈΠ΄Π°ΡΠΎΠ² ΠΏΡΠΈ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠ΅ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ΅ΡΠΎΠ΄Π° Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΠΉ ΡΠΎΠ»ΡΡΠΎΠΉ ΠΊΠΈΡΠΊΠΈ
Investigation of the expression level of genes-markers of proliferative activity in the mucosa at normal and various pathologies of the colon
Background. The search for molecular markers of colon diseases allowing highly specific and sensitive identification and differentiation of pathological processes is a clinically important problem. Expression levels of genes responsible for proliferation can reflect the changes in the affected tissues. The study objective is to perform comparative analysis of molecular and genetic markers of proliferative activity in benign and malignant neoplasms of the colon. Materials and methods. Analysis of the changes in proliferation markers (CCND1, Ρ-MYC, Ki-67, HER2neu, TERT) in adenocarcinoma of the colon (n = 259), resection margin (about 15β20 cm from the tumor lesion) (n = 251), unchanged colon mucosa from healthy donors (n = 247), polyps (n = 28), unchanged colon mucosa intestinal polyposis (10β15 cm from the polyp) (n = 75) was performed using RT-PCR. Results and conclusion. It was shown that morphologically unchanged tissue of intestinal mucosa in malignant tumors has significant differences from normal tissue of healthy donors. Significant differences in the level of expression of genes responsible for the processes of proliferation, Ρ-MYC, CCND1, TERT were found in benign hyperproliferative diseases (polyps). Moreover, these changes were specific to the type of pathological process, which allows us to consider these genes as the most promising candidates in the development of a differential method for diagnosing colon diseases